QurAlis Begins Phase 1 Trial of QRL-101 for ALS Treatment
Originally Published 1 year ago — by ALS News Today
Quralis has initiated a Phase 1 clinical trial for QRL-101, a novel treatment aimed at reducing nerve cell overactivation in amyotrophic lateral sclerosis (ALS) patients, potentially slowing disease progression. The trial, conducted in the Netherlands, will assess the safety, tolerability, and pharmacological properties of QRL-101. This first-in-class therapy targets Kv7.2/7.3 ion channels to control motor neuron hyperexcitability, a key factor in ALS progression. Results from this study, along with parallel research, will guide future development of QRL-101.